ASND Ascendis Pharma
Price Chart
Executive Summary
Ascendis Pharma announced sustained efficacy and safety data from the Phase 3 PaTHway Trial of TransCon PTH (YORVIPATH) in hypoparathyroidism through 3.5 years (Week 182). 86% of patients met the multi-component endpoint, 89% completed the trial, and key renal, bone, and quality-of-life benefits were maintained with no new safety signals. This positive long-term data reinforces the drug's profile and supports continued commercial adoption, though the stock has historically underperformed following prior positive reports.
Actionable Insight
The sustained efficacy and safety data through 3.5 years de-risks YORVIPATH's long-term profile and supports continued prescription growth. Monitor upcoming quarterly earnings for revenue ramp and any competitive developments. The stock has historically sold off after positive news (T+20 avg -4.8%), so consider near-term volatility despite the fundamentally bullish data.
Key Facts
- 86% of patients were responders for the multi-component endpoint (normocalcemia, no active vitamin D, ≤600 mg/day calcium) at Week 182.
- 89% of patients completed the 3.5-year trial.
- 100% of patients achieved independence from active vitamin D; 96% from therapeutic calcium doses.
- Mean eGFR increased by 11.0 mL/min/1.73 m² from baseline and was maintained through Week 182, contrasting with expected age-related decline.
- Mean 24-hour urine calcium normalized within 26 weeks and remained normal through Week 182.
- No new safety signals; no discontinuations related to study drug; no anti-PTH antibodies developed.
- TransCon PTH is already approved as YORVIPATH in the US, EU, and other jurisdictions.
- Trial enrolled 82 adults (85% post-surgical, 15% non-surgical hypoparathyroidism).
Financial Impact
Positive long-term data supports YORVIPATH's commercial potential in hypoparathyroidism, a chronic disease with no other PTH-replacement therapy. No revenue or financial figures were disclosed in the press release.
Risk Factors
- Historical pattern of stock declines following positive Ascendis announcements (T+20 avg -4.8%, 25% win rate).
- Competition from other hypoparathyroidism therapies in development.
- Pricing and reimbursement challenges in key markets.
- Potential for regulatory setbacks in additional jurisdictions.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3311416 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 13, 2026
1d ago
|
Press Release
| — | awaiting T+1 | — | — |
|
Jun 12, 2026
3d ago
|
6-K
| $215.32 awaiting T+1 | awaiting T+1 | — | $218.06 (+1.27%) |
|
Jun 2, 2026
12d ago
|
Insider Cluster
| $216.79 $218.84 | ▲ +0.95% | ▲ +0.55% | $218.06 (+0.59%) |
|
May 19, 2026
26d ago
|
ANALYST-UPGRADE
| $237.98 $241.34 | ▲ +1.41% | ▲ +0.37% | $218.06 (−8.37%) |
|
May 16, 2026
29d ago
|
ANALYST-UPGRADE
| $170.74 $162.84 | ▼ −4.63% | ▼ −3.78% | $218.06 (+27.71%) |
|
May 7, 2026
5w ago
|
6-K
| $246.14 $238.66 | ▼ −3.04% | ▼ −3.87% | $218.06 (−11.41%) |
|
May 7, 2026
5w ago
|
6-K
| $246.14 $238.66 | ▼ −3.04% | ▼ −3.87% | $218.06 (−11.41%) |
|
May 6, 2026
5w ago
|
Press Release
| $246.14 $246.14 | · 0.00% | ▼ −0.83% | $218.06 (−11.41%) |
|
Apr 21, 2026
7w ago
|
6-K
| $240.29 $231.05 | ▼ −3.85% | ▼ −4.86% | $218.06 (−9.25%) |
|
Apr 16, 2026
8w ago
|
ANALYST-UPGRADE
| $242.95 $244.48 | ▲ +0.63% | ▼ −0.58% | $218.06 (−10.24%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access